Fields G B, Noble R L
Department of Pharmaceutical Chemistry, University of California, San Francisco.
Int J Pept Protein Res. 1990 Mar;35(3):161-214. doi: 10.1111/j.1399-3011.1990.tb00939.x.
9-Fluorenylmethoxycarbonyl (Fmoc) amino acids were first used for solid phase peptide synthesis a little more than a decade ago. Since that time, Fmoc solid phase peptide synthesis methodology has been greatly enhanced by the introduction of a variety of solid supports, linkages, and side chain protecting groups, as well as by increased understanding of solvation conditions. These advances have led to many impressive syntheses, such as those of biologically active and isotopically labeled peptides and small proteins. The great variety of conditions under which Fmoc solid phase peptide synthesis may be carried out represents a truly "orthogonal" scheme, and thus offers many unique opportunities for bioorganic chemistry.
9-芴甲氧羰基(Fmoc)氨基酸在十多年前首次用于固相肽合成。从那时起,通过引入各种固相载体、连接基团和侧链保护基团,以及对溶剂化条件的进一步了解,Fmoc固相肽合成方法得到了极大的改进。这些进展带来了许多令人瞩目的合成成果,例如生物活性肽、同位素标记肽和小蛋白质的合成。Fmoc固相肽合成可以在多种多样的条件下进行,这代表了一种真正的“正交”方案,因此为生物有机化学提供了许多独特的机会。